Cannabis acute use impacts symptoms and functionality in a cohort of antipsychotic naïve First Episode of Psychosis individuals

Alcover

Early Intervention Psych

et al. 2020

Aim: To explore the relationship between cannabis use and metabolic syndrome (MetS) among those who have experienced first episode psychosis (FEP).Methods: A retrospective analysis of 404 participants enrolled in the Recovery After Initial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) was conducted.Using multiple logistic regression, we investigated the correlation between cannabis use and rate of MetS at baseline and across time as well as the specific metabolic derangements among cannabis users and abstainers.Results: Although cannabis users had similar rates of MetS at baseline when compared with abstainers, those who used cannabis at any time during the study period tended to have lower triglycerides and elevated high-density lipoprotein (HDL). Cannabis users were less likely to develop MetS, relative to nonusers.Conclusions: Cannabis use may be associated with lower incidence of MetS in patients who have experienced FEP. Further research is indicated to develop these observations.

Section: Introductionmentioning

confidence: 99%

Cannabis use and metabolic syndrome among clients with first episode psychosis

Alcover

Early Intervention Psych

et al. 2020

Drug and Alcohol Review

“…In a subset analysis, occasional (i.e., non‐frequent use) and habitual (i.e., frequent use without problems) cannabis use were associated with better quality of life, anxiety and depression scores compared to non‐cannabis using controls (aOR: 0.52–0.24, p <0.01); conversely, dysfunctional (cannabis use with problems) use was associated with worse depression scores compared to controls (aOR: 1.33, p <0.05) [120]. Studies with first‐episode psychosis samples identified that acute cannabis use increased excitement symptoms ( p = 0.021, Cohen's d = 0.34) and predicted worse functionality and clinical presentation ( p < 0.01, R 2 = 0.18) during pharmacological antipsychotic treatment compared to controls [121], while, conversely, cannabis users had fewer brain abnormalities (based on magnetic resonance imaging) and less attentional and executive impairments compared to healthy, non‐drug users control ( p < 0.05) [122]. Furthermore, early‐onset (<15 years) cannabis users presented worse sustained attention, impulse control, and executive functioning metrics than late‐onset (>15 years) and non‐drug user controls ( F = 3.4–7.0, p < 0.05) among chronic cannabis users assessed in a substance treatment program ( n = 44–55/group) [123].…”

Section: Resultsmentioning

confidence: 99%

Cannabis use, risk behaviours and harms in Brazil: A comprehensive review of available data indicators

Daldegan‐Bueno

Lindner

Kovaleski

et al. 2022

Issues: Cannabis use and related health/social outcome indicator data for Brazil-where non-medical cannabis is generally illegal-are limited. Approach: Towards a comprehensive overview of relevant indicators, we searched primary databases by combining MeSH-index terms related to cannabis, geographic location and subtopic terms (e.g., use, health, mortality) focusing on cannabis use and key outcome indicators in Brazil since 2010. In addition, relevant 'grey literature' (e.g., survey reports) was identified. Key indicator data were mainly narratively summarised.

“…The use of cannabis was assessed by asking participants how many days they used cannabis on average in the past 30 days [ 21 ]. Patients were categorized into three different categories: nonusers, non-daily users, and daily users [ 22 ].…”

Section: Methodsmentioning

confidence: 99%

The relationship between substance use and self-reported aspects of social functioning in patients with a psychotic disorder

van der Heijden,

Kikkert,

de Haan

et al. 2024

Eur. Psychiatr.

Background. In patients with a psychotic disorder, rates of substance use (tobacco, cannabis, and alcohol) are higher compared to the general population. However, little is known about associations between substance use and self-reported aspects of social functioning in patients with a psychotic disorder. Methods. In this cross-sectional study of 281 community-dwelling patients with a psychotic disorder, linear regression models were used to assess associations between substance use (tobacco, cannabis, or alcohol) and self-reported aspects of social functioning (perceived social support, stigmatization, social participation, or loneliness) adjusting for confounders (age, gender, and severity of psychopathology). Results. Compared to nonsmokers, both intermediate and heavy smokers reported lower scores on loneliness (E = À0.580, SE = 0.258, p = 0.025 and E = À0.547, SE = 0,272, p = 0.046, respectively). Daily cannabis users reported less social participation deficits than non-cannabis users (E = À0.348, SE = 0.145, p = 0.017). Problematic alcohol use was associated with more perceived social support compared to non-alcohol use (E = 3.152, SE = 1.102, p = 0.005). Polysubstance users reported less loneliness compared to no users (E = À0.569, SE = 0.287, p = 0.049). Conclusions. Substance use in patients with psychosis is associated with more favorable scores on various self-reported aspects of social functioning.